Merck’s oral PCSK9 inhibitor, enlicitide, produced LDL cholesterol reductions up to 60% in a Phase 3 trial testing the pill on patients already taking statins, the company reported. The multicenter study enrolled about 2,900 high‑risk patients and showed two‑thirds achieved at least a 50% LDL reduction versus placebo. The result meets Merck’s long‑standing objective to match injectable PCSK9 monoclonal antibodies with an oral therapy. If regulators validate the data, an oral, once‑daily PCSK9 could alter cholesterol management logistics and competitive dynamics across cardiometabolic portfolios.